2025-11-06 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX), incorporating the provided data and presenting it in an English report format:

**Report: TG Therapeutics (TGTX) Stock Analysis**

**1. Relative Performance & Company Overview**

*   **Ticker:** TGTX
*   **Company:** TG Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**Key Performance Metrics vs. S&P 500 (VOO):**

*   **TGTX Cumulative Return:** 81.61%
*   **VOO Cumulative Return:** 99.52%
*   **Absolute Divergence:** -20.8% (TGTX underperformed VOO by this amount)
*   **Relative Divergence:** 19.7% (This indicates TGTX's current divergence relative to its historical range of divergence compared to the VOO, placing it towards the lower end of its historical relative performance).

**Alpha/Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta   | Cap (B) |
|------------|--------|--------|--------|--------|---------|
| 2015-2017  | -5.0%  | 73.5%  | -33.0% | -0.0   | 1.3     |
| 2016-2018  | -12.0% | 73.5%  | -27.0% | -0.0   | 0.7     |
| 2017-2019  | 74.0%  | 74.1%  | 52.0%  | 0.0    | 1.8     |
| 2018-2020  | 316.0% | 74.1%  | 293.0% | 0.1    | 8.2     |
| 2019-2021  | 124.0% | 74.1%  | 78.0%  | 0.3    | 3.0     |
| 2020-2022  | -71.0% | 77.8%  | -71.0% | -0.0   | 1.9     |
| 2021-2023  | -284.0%| 77.8%  | -285.0%| -1.1   | 2.7     |
| 2022-2024  | 56.0%  | 77.8%  | 36.0%  | -1.0   | 4.8     |
| 2023-2025  | 82.0%  | 80.7%  | 18.0%  | -0.1   | 5.4     |

**Analysis:**

*   TGTX has underperformed the S&P 500 over the specified period.
*   The relative divergence suggests the underperformance is within its historical range, but closer to the weaker end.
*   The Alpha/Beta analysis shows varying performance across different periods.  Notably, the later years (2021-2025) show negative Beta, indicating inverse correlation. High Alpha values have been seen in the past, particularly from 2018 to 2021, but recent Alpha figures have been less impressive. The MDD (Maximum Drawdown) remains consistently high, indicating significant volatility.

**2. Recent Price Action**

*   **Last Close:** $33.92
*   **Last Market Data:** Price: $33.86, Previous Close: $33.81, Change: $0.15 (Slight positive movement)
*   **5-Day Moving Average:** 34.038
*   **20-Day Moving Average:** 34.3472
*   **60-Day Moving Average:** 32.7381

**Analysis:**

*   The current price is slightly below the 5-day and 20-day moving averages but above the 60-day moving average. This suggests a possible short-term downward trend, with the price potentially finding support around the 60-day MA. The "change" of $0.15 is not particularly large, so doesn't indicate a major volatility event.

**3. Market Risk Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 42.70 (Neutral)
*   **PPO:** -0.4064 (Bearish - indicates the short-term moving average is below the long-term moving average)
*   **Hybrid Signal:** cash_80%_Sell (Sell 80% of holdings; Cash Ratio: 80% on 2025-10-16)
*   **Recent (20-day) Relative Divergence Change:** -1.3 (Short-term decline)
*   **Expected Return:** -116.4% (Long-term, relative to S&P 500)

**Analysis:**

*   Despite a "High Investment Recommended" MRI, the Hybrid Signal strongly advises reducing holdings. This conflicting signal requires careful consideration.
*   The RSI is neutral, not indicating overbought or oversold conditions.
*   The PPO suggests a potential short-term bearish trend.
*   The negative expected return is a significant concern, suggesting substantial underperformance compared to the S&P 500 over the long term, if the current trend continues. The recent decline in relative divergence reinforces this cautionary outlook.

**4. Recent News & Significant Events**

*   **Positive Headlines:** Several headlines highlight strong Q3 earnings and revenue, exceeding estimates.  Zacks sees TGTX as a top growth stock for the long term.
*   **Cautionary Headlines:**  Simply Wall St. points out margin issues challenging the growth-driven profitability narrative and explores the valuation. Investor's Business Daily notes a caveat to the profit views.

**Analysis:**

*   Recent news presents a mixed picture. While the Q3 results are positive, concerns about margins and valuation need to be considered. The analyst opinions need to be considered in light of these competing narratives.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~1.78 on a 1-5 scale)
*   **Opinions:** 7 analysts
*   **Target Price:** Average: $44.29, High: $60.00, Low: $13.00
*   **Recent Rating Changes:** No changes provided in the data.

**Analysis:**

*   Analyst consensus is generally positive, with a "Buy" rating. However, the wide range in target prices ($13.00 - $60.00) indicates considerable uncertainty and differing opinions on the stock's future performance.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출         |
|------------|------|--------------|
| 2025-08-08 | 0.19 | 0.14 B$      |
| 2025-05-09 | 0.03 | 0.12 B$      |
| 2024-11-07 | 0.03 | 0.08 B$      |
| 2024-08-09 | 0.05 | 0.07 B$      |
| 2025-08-08 | 0.05 | 0.07 B$      |

**Analysis:**

*   The most recent quarter (2025-08-08) shows a significant jump in EPS to 0.19, with revenue at 0.14B. This suggests strong recent performance. The data from 2024 shows a trend of gradual increase.

**6. Financial Information (Revenue, Profitability, Capital)**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.14B    | 86.58%        |
| 2025-03-31 | $0.12B    | 87.14%        |
| 2024-12-31 | $0.11B    | 85.77%        |
| 2024-09-30 | $0.08B    | 88.86%        |
| 2024-06-30 | $0.07B    | 88.70%        |

| Quarter    | Equity    | ROE    |
|------------|-----------|--------|
| 2025-06-30 | $0.28B    | 10.20% |
| 2025-03-31 | $0.24B    | 2.13%  |
| 2024-12-31 | $0.22B    | 10.49% |
| 2024-09-30 | $0.19B    | 2.02%  |
| 2024-06-30 | $0.18B    | 3.87%  |

**Analysis:**

*   Revenue is trending upward, indicating growth in the company's sales.
*   Profit margins are consistently high, suggesting good cost management. However, the Simply Wall St. headlines regarding "margin miss" suggest there might be concerns about future sustainability of these high margins or that there may be a decline from an even higher level previously.
*   Equity is increasing, suggesting the company is building its asset base.
*   ROE (Return on Equity) is volatile.

**7. Comprehensive Analysis & Conclusion**

Overall, the analysis of TGTX presents a mixed outlook:

*   **Positives:** Recent Q3 earnings were strong, and analysts have a generally positive view. Revenue and profit margins are currently healthy.
*   **Negatives:** TGTX has underperformed the S&P 500.  The hybrid signal suggests selling, and the expected return is negative. The analyst target prices show a wide range of uncertainty. The high MDD indicates significant volatility.
*   **Key Considerations:** The conflicting signals from the MRI and Hybrid Signal, along with the potential margin issues flagged in the news, warrant a cautious approach. The negative expected return needs careful investigation. The analyst opinions and target prices need to be considered with the understanding that there is a wide range of uncertainty.
*   **Recommendation:** Given the conflicting signals and potential risks, a neutral to slightly negative outlook may be warranted. Investors should carefully consider their risk tolerance, investigate the reasons behind the negative expected return, and monitor the company's future performance, particularly regarding margin sustainability. A "wait and see" approach might be prudent.
